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Introduction
Aspidosperma subincanum Mart. ex A. DC., Apocynaceae, is a 
Brazilian tree commonly known as “guatambu”. The bitter 
tonic of its bark is known by the indigenous population 
to stimulate genitourinary, circulatory and respiratory 
functions, reduce fever and attenuate spasms. These 
physiological activities are caused by its principal alkaloid, 
uleine (1). Since 2004, Brazilian researchers have reported 
a broad spectrum of in vitro antimicrobial activity of an 
uleine-rich plant extract against pathogens, as well as 
having gastro-protective effects (Baggio et al., 2005), elicits 
alterations of vascular and non-vascular smooth muscle 
responsiveness (Rattmann et al., 2005), produces nitric 
oxide (Souza et al., 2007), interferes with the inflammatory 
response (Nardin et al., 2008), regulates the immune system 
(Nardin et al., 2010) and has anticholinesterase activity 
(Seidl et al., 2010). All effects are attributed to the alkaloid 
uleine.
A research group from the Federal University of Paraná 
extracted the alkaloid uleine from Himatanthus lancifolius, and 
our laboratory endeavoured to purify uleine from the bark 
of Aspidosperma subincanum with the aim of concentrating 
uleine to be used as food supplement. For this purpose, it was 
imperative to verify the toxicity generated by the contaminant 
ellipticine (2).
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A B S T R A C T
The bark of the Brazilian tree Aspidosperma subincanum Mart. ex A. DC., Apocynaceae, has been 
characterised, and its constituents concentrated to obtain an uleine-enriched extract with the 
aim to produce food supplements. The concentration of the contaminant alkaloid ellipticine 
was assessed, and its potential to elicit toxic effects on consumers evaluated. It was found 
that this alkaloid posited no danger. 
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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Plant material providers have a strong tendency to fail to 
distinguish between plants that possess similar medicinal effects 
and sell one for the other, this first publication exposes the 
characterisation of three different plants, namely Geissospermum 
laeve (Vell.) Miers, Apocynaceae; Tabebuia impetiginosa (Mart. ex DC.) 
Standl., Bignoniaceae; and Aspidosperma subincanum, three species 
easily confounded; and the potential toxic effect of ellipticine (2) 
present in trace amounts in the bark of A. subincanum. 
Materials and methods
Plant material
Barks of Geissospermum laeve, (Vell.) Miers, Apocynaceae, 
Tabebuia impetiginosa (Mart. ex DC.) Standl., Bignoniaceae, and 
Aspidosperma subincanum Mart. ex A. DC., Apocynaceae, were 
commercially acquired in São Paulo (Brazil). The identification 
and authentication of the bark of A. subincanum was performed 
at the Laboratory of Pharmacognosy and Galenics of the 
University of Antwerp (Belgium) (Vlietinck, 2000). 
Routinely, a sample is ordered and analysed in our 
laboratory (Arolab) by high-pressure liquid chromatography 
(HPLC) for conformity with the specifications and stored dry 
until processing. Samples of each lot are kept for reference at 
the laboratory.
Methods
The methods used in this study, thin layer chromatography 
(TLC), high pressure liquid chromatography (HPLC) and 
mass spectrum analysis, are all well-known methods by 
the investigators active in these fields and do not need an 
exhaustive description. Specific details will be given in the 
results section. 
The barks of the three species were extracted and the 
alkaloids content verified by HPLC.
Extraction
The barks were mixed with alcohol at 70° in a ratio 1:10 under 
agitation, and heated with microwaves until a temperature 
of 50°C was reached. The extraction was done using 1000 mg 
of microgranules, refluxed for 45 min at 90°C in ethanol 70°, 
acidified with 2% H3PO4, and the yield was filtered.
HPLC analysis
Conditions
An ODS C18 column 150 × 4.6; gradient: t0 10% ACN/H2O, 1.34 g 
KH2PO4, 220 mg 1-heptane sulfonic acid, 0.7 ml triethylamine qsp 
1000 cc, pH 2.8 by H3PO4; t30 40% ACN; at t35, the concentration 
of ACN was reduced from 40% to 10 % and, at t40, the run ended. 
The peaks are integrated except the peak of injection; calibration 
was done with codeine as control (0.5 mg/10) 
Sample preparation
The liquid concentrate (1 g) was mixed with  ammonia at 30 % 
(3 ml) and ethyl acetate (20-25 ml) under agitation for 15 min. 
The supernatant was recuperated and transferred to a vial; the 
rest is exhausted three times with ethyl acetate and added to 
the decantation vial. The organic phase is extracted three times 
with water (150 ml) and sulphuric acid (2%), and the aqueous 
phases recuperated. The aqueous phase was alkalinized with 
ammonia (30%) to reach pH 9 (9-12 ml); extracted thrice with 
50 ml dichloromethane and washed three times with 70 ml 
water. The dichloromethane phase is evaporated to dryness, 
and further dissolved in 20 ml water with 2% phosphoric acid.
Uleine (1) and ellipticine (2) were characterised by mass 
spectrum analysis of the previously isolated molecules
Results
Drug identification
Barks of Geissospermum laeve (Vell.) Miers, Apocynaceae, 
Tabebuia impetiginosa (Mart. ex DC.) Standl., Bignoniaceae, and 
Aspidosperma subincanum Mart. ex A. DC., Apocynaceae, were 
chosen for comparison because they are all three endowed 
with similar desirable medicinal properties and are commonly 
interchanged by vendors of these prime material. 
The HPLC chromatograms of their extracts differ 
substantially and make them easily recognisable (Figs. 1, 2 
and 3) and allow the rejection of any material that does not 
conform to the specifications. 
Molecule characterisation
Is the molecule eluting last in the HPLC of Aspidosperma 
subincanum extract uleine?
To confirm the chemical identity, the material isolated 
by HPLC was submitted to a mass spectrum analysis, which 
is a gas-chromatographic method of analysis of the atoms 
composing a molecule. The mass spectra of uleine (1) showed 
its molecular mass at m/z 266. Additional characteristic signals 
were detected at m/z 237, 223, 209, 194, 180 and 167. These are 
explained according to two simultaneously occurring schemes. 
The fragment M+-C2H5 could be explained by the location of 
the ion bond C-14/15, which is activated by the allyl position, 
and the breaking of the connection and loss of the ethyl radical, 
with subsequent formation of fragment m/z 237. Alternatively, 
the loss of the C-21 substituent with a hydrogen transfer with 
N-methyl formation, could form the fragment m/z 181; the 
subsequent loss of the benzyl hydrogen of m/z 181 or the loss 
of the amine side chain will form the fully conjugated species 
m/z 180, in accordance to previous studies (Joule and Djerassi, 
1964; Manske and Rodrigo, 1965).
The ion m/z 209 can be formed by rearrangement of 
hydrogen through the six membered ring intermediary, 
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Figure 1 – HPLC profile of Geissospermum laevis extract. The marker that elutes first, after two minutes, is codeine.
Figure 2 – HPLC profile of Aspidosperma subincanum extract. The marker that elutes first is codeine. The major peak, which 
elute last, is uleine.
Figure 3 – HPLC profile of Tabebuia impetiginosa extract. The marker that elutes in front is codeine.
breaking the benzylic additional bond with the loss of a methyl 
radical ion, which causes the formation of ion m/z 194. Other 
fragments are present at m/z 180, 151, 127, 112, 98, 77, 58 e 32 
(Joule and Djerassi, 1964).
Discussion
Ellipticine
Ellipticine (2) is a toxic alkaloid present in minute amounts 
in the bark of Aspidosperma. The French Agency for Food 
Safety (AFSSA) allows the presence of contaminants in food 
supplements inferior to 1% if their traditional use has been 
proven innocuous satisfactorily (Bertha et al., 2003). Two 
considerations must be taken into account for the evaluation of 
the deleterious impact of ellipticine on consumers: how much 
is there of this substance in the purified encapsulated uleine 
food supplement and how toxic is this amount absorbed by 
mouth?
Concentration of ellipticine
A concentration of 0.063% of ellipticine and derivates 
was detected in a food supplement made from the bark of 
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Aspidosperma subincanum (Table 1). Accordingly, 0.26 mg of 
ellipticine and isomers were present in a 420 mg capsule 
(Angenot, 2004). Although the recommendation is a daily 
intake of three capsules, the investigator assumed an intake 
of six capsules, which accounts to a daily intake of 1.6 mg 
of ellipticine and derivate. This increased, amount has 
been deemed toxic for the consumer in the long run, and 
especially during pregnancy. To consolidate this argument, the 
abandonment of the use of ellipticine as an anticancer agent 
was encouraged due to its crippling collateral toxic activities. 
The conclusions of this investigation stated that mutagenic 
and teratogenic effects in vivo only led to the rejection of this 
food supplement by the Belgian Ministry of Health (Demotte, 
2007) and by the French Ministry of Economy (Constans, 2008). 
The total concentration of ellipticine reported (0.063%) 
in the capsules is well under the lower limit of tolerance of 
contaminants of food supplements defined by the AFSSA, 
which is 1%. Below this concentration, the contaminant is 
ignored.
on diploid cells, although these may suffer from clastogenesis 
(Moore et al., 1987). However, no corroboration of these 
results could be found in studies performed in vivo, where the 
drug may be administered via various routes, which impact 
significantly on drug assimilation.
In vivo, ellipticine administered intravenously in rats induces 
chromosomic aberrations in bone-marrow cells (Sakamoto-
Hojo et al., 1988). However, to have an effect, ellipticine must 
first be metabolised by oxidation of 13-hydroxyellipticine and 
ellipticine N2-oxyde via cytochrome P450 3A4 (Stiborová et 
al., 2004). In the introduction of their publication, the authors 
mentioned that ellipticine showed little undesirable side 
effects when used as an anticancer agent. This statement 
contradicts the claim made by Angenot.
Why is ellipticine a poor anticancer drug and why has it little 
side effects in vivo?
Ellipticine solubilises poorly in salty water. Human blood 
is salty and precipitates ellipticine. Ellipticine injected 
intravenously is not excreted via the kidneys but 84% of it is 
found in the faeces. To overcome the poor solubility of the 
genuine drug in media and use it as an anticancer agent in 
humans, it was solubilised in glucose by coupling it to acetate. 
The elliptitium acetate was injected three successive weeks at 
massive doses of 80 mg/m2/day, three days a week, with little 
response not due to intolerable side effects. It was abandoned 
because the ellipticine acetate induced the formation of 
antibodies. As a food supplement, the ellipticine is present 
at the dose of 0.063% per capsule, well below the lower-limit 
of 1% admitted for contaminants of food supplements, and is 
administered orally. In the stomach, high acidity precipitates 
it. In addition, the enzyme cytochrome P450 3A4 needed to 
metabolize the ellipticine into an active anticancer agent is 
not present in the stomach.
Traditional uses of extracts of Aspidosperma subincanum 
confirm these experimental observations: taken orally, extracts 
of Aspidosperma subincanum are non-toxic and can be used as 
food supplements. The plant was introduced in Europe in 
1878. No report of toxicity was ever registered. The Belgian 
Ministry of Health admitted the use of extracts of Aspidosperma 
subincanum until 2007, and this food supplement was not 
reported to be toxic between 1878 and 2007. Exhaustive toxicity 
studies performed on mice (2000 mg/kg, 28 days, six days/
week), rats (2000 mg/kg, single dose) and rabbits (500 mg/kg, 
28 days, six days/week) confirmed that the food supplement is 
harmless when administered per os during a month at doses 
60 times the average recommended daily dose for humans (SGS 
Lab Simon S.A. 1999 and 2000). Teratogenic and mutagenic 
effects were not detected.
Conclusion
The study of the properties of uleine has been actively pursued 
for the last two decades by the Laboratory of Pharmacognosy 
of the University of Paraná, Arolab; aiming to fully characterise 
the Aspidosperma plant and Parabolic Biologicals established the 
potential toxic activity of the alkaloid ellipticine that this plant 
contains. It was concluded that ellipticine posits no danger 
Bark
Content of ellipticine (2) and 
derivates (%)
Methanol extract 0.012
Ethyl acetate extract 0.024
Ethanol 50% extract 0.018
Capsules
Ethyl acetate 0.043
Ethyl acetate + NH4OH 0.020
Total 0.063
Table 1
Ellipticine (2) and derivates contents present in the bark of 
Aspidosperma subincanum.
Toxicity of ellipticine.
The toxicity of ellipticine varies considerably according to its 
evaluation in vitro and in vivo, and to route of administration. 
Food supplements are supposed to be absorbed exclusively by 
mouth. Studies in vitro showed promise for the use of ellipticine 
as an anticancer agent but in vivo assays failed to confirm it. 
A study performed in vitro demonstrated that ellipticine 
attaches to topoisomerase II, even in the absence of 
DNA (Froelich-Ammon et al., 1995).  Furthermore, the 
topoisomerase-ellipticine complex attaches exclusively to 
abnormal portions of DNA (René et al., 2007). The claim that 
ellipticine is mutagenic because it modifies DNA is questioned 
because this molecule does not modify normal double-
stranded DNA. It was shown in vitro that ellipticine induces the 
“natural” death of cancer cells by apoptosis (Kuo et al., 2005). 
This study suggested ellipticine to hold anticancer properties, 
instead of its alleged toxicity for normal diploid cells. Several 
in vitro studies proposed ellipticine to induce aberrations (i.e. 
clastogenesis) in human lymphocytes (Sakamoto-Hojo et al., 
1988). It has been documented that ellipticine is mutagenic 
essentially for tumoral cells and have little mutagenic effects 
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for the use of this plant as a food supplement, regardless the 
dose ingested.
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